NasdaqGS:BIOAPharmaceuticals
BioAge Labs (BIOA) Following QUELL CV Trial Start Is The Stock A Bargain
Why the QUELL-CV Trial Matters for BioAge Labs Stock
BioAge Labs (BIOA) has moved its lead drug candidate, BGE-102, into the Phase 2 QUELL-CV trial, a randomized, placebo-controlled study targeting cardiovascular risk in adults with obesity and elevated inflammation.
The trial plans to enroll about 160 participants over 12 weeks of once daily dosing, testing three oral dose levels against placebo. The primary focus is change in high-sensitivity C-reactive protein, with additional inflammatory...